4.8 Article

An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression

Journal

CANCER CELL
Volume 30, Issue 3, Pages 432-443

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2016.08.002

Keywords

-

Funding

  1. NCATS NIH HHS [UL1 TR001863] Funding Source: Medline
  2. NCI NIH HHS [R01 CA143971] Funding Source: Medline

Ask authors/readers for more resources

RhoGDI2 specifically suppresses bladder cancer metastasis but not primary tumor growth, which involves tumor-associated macrophages. We report that macrophage-secreted osteopontin binds to CD44s on the tumor cells and promotes invasion and clonal growth. These effects are RhoGDI2-sensitive and require CD44s binding to the Rac GEF TIAM1. Osteopontin expression correlates with tumor aggressiveness and poor clinical outcome in patients. Inhibiting this pathway potently blocked lung and lymph node metastasis; however, primary tumors and established metastasis were less sensitive. Osteopontin-CD44s-TIAM1 promotes clonal growth in vitro but not at high cell density. These data identify osteopontin-CD44-TIAM1-Rac1 axis as a RhoGDI2-sensitive pathway and potential therapeutic target in bladder cancer metastasis. They also elucidate the mechanism behind RhoGDI2 specificity for metastasis over established tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available